The United Kingdom and the United States have reached a important bilateral deal that will guarantee no import taxes on British medicine products going into the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase funding on medicines through the NHS. This move guarantees that import taxes on these key products will remain at zero for a duration of the next three years.
This development is in response to previous threats to significantly raise tariffs on patented drug imports, with increases mentioned up to one hundred percent.
"This deal between the United Kingdom reinforces the international landscape for innovative medicines and introduces long-overdue equity to U.S.–U.K. pharmaceutical trade," an announcement said.
Trade Impact
Pharmaceuticals are one of the the United Kingdom's biggest exports to the US, which is by far the largest market for leading companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period to the end of the third quarter, the UK shipped drugs totaling £11.1bn to the US. This value accounted for a significant portion of total UK exports in that span.
"This agreement safeguards jobs, boosts capital expenditure and paves the way for the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Key UK Commitments
The deal involves several notable changes from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to increase overall health service expenditure on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to control costs will be restricted at 15%. Last year, repayments exceeded twenty percent.
Industry Background
The deal takes place against a protracted tension between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
The disagreement were intensified by assertions that American customers were charged significantly more for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or scrapped, while substantial expansions have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS must invest a greater share on drugs, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
